News | February 22, 2012

Theragenics Acquires Core Oncology’s Prostate Brachytherapy Customer Base

February 21, 2012 — Theragenics Corp.,a medical device company serving the surgical products and prostate cancer treatment markets, announced that it has purchased Core Oncology’s prostate brachytherapy customer base. The asset acquisition was effective on Feb. 17, 2012. The total purchase price is structured as an “earn-out” equal to one times the actual revenue generated from the acquired customers over the twelve-month period beginning September 2012 and ending August 2013 in excess of a $2.5 million threshold amount. Theragenics paid $3.8 million in cash at closing as prepayment of a portion of the earn-out, and will make quarterly earn-out payments thereafter. The company expects to fund the quarterly earn-out payments from operating cash flow and existing cash balances.

“The Core transaction and additional iodine business demonstrates our continuing commitment to this treatment, the physicians and the patients who depend on it,” said M. Christine Jacobs, chairman and CEO of Theragenics Corporation. “The Core customers are in good hands.”

Travis Gay, CEO of Core Oncology, said, “Theragenics has been recognized as a leader and has been a valued partner of Core’s. I am confident that Theragenics will continue the outstanding quality and service to which the Core customers and patients they serve have grown accustomed.”

For more information: www.theragenics.com

Related Content

Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation
News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018
An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with...
Prostate Brachytherapy Shows Low Incidence of Short-Term Complications
News | Brachytherapy Systems | October 31, 2018
A new analysis of nearly 600 men receiving brachytherapy for prostate cancer shows overall procedure-related...
Prostate Radiotherapy Outcomes Better for African-Americans Than Caucasian Patients according to a study presented at ASTRO 2018. #ASTRO #ASTRO18 #ASTRO2018
Feature | Prostate Cancer | October 30, 2018
October 30, 2018 — While popular beliefs and population data suggest that African-American men are at higher risk of
News | Brachytherapy Systems, Women's Healthcare | October 25, 2018
iCAD Inc. announced new clinical research demonstrating positive outcomes supporting the use of the Xoft Axxent...